Invitation to Submit Proposals under Framework Agreements 2023/494 - Medicines for Chronic Hepatitis C and 2025/1303 - Various Medicines for the Acquisition of Medicines for Chronic Hepatitis C

This tender, reference 2026/0221, is an invitation to submit proposals for the acquisition of medicines for chronic Hepatitis C. The procurement will be conducted under two existing framework agreements: 2023/494, specifically for Medicines for Chronic Hepatitis C, and 2025/1303, which covers Various Medicines. The primary objective is to procure specific medications required for the treatment of chronic Hepatitis C. This call for proposals aims to select suppliers who can provide these essential drugs efficiently and cost-effectively, leveraging the established framework agreements. Bidders are expected to offer the specified Hepatitis C medications, meeting all quality, safety, and efficacy standards. The evaluation will focus on the proposed pricing, delivery capabilities, and compliance with the terms of the framework agreements. This procurement is critical for ensuring that patients suffering from chronic Hepatitis C have access to the necessary treatments. The successful bidder will be responsible for the supply of these vital medications, contributing to public health outcomes.

This is a supplies contract in the health and medical services, Monitoring Evaluation and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 379,500.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.